Latest On Diffusion Pharmaceuticals Inc (DFFN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-03-31 03:39 EST | News | Diffusion to merge with EIP Pharma in all-stock deal | N/A |  |
| 2022-11-15 17:47 EST | News | Diffusion Pharmaceuticals GAAP EPS of -$1.37 beats by $0.69 | N/A | |
| 2022-10-25 10:06 EST | News | Diffusion to undertake strategic review, options may include company sale | N/A | |
| 2022-08-16 23:47 EST | News | Diffusion raised to Buy at H.C. Wainwright after Q2 update on lead asset | N/A | |
| 2022-08-12 17:49 EST | News | Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02 | N/A | |
| 2022-05-13 10:49 EST | News | Diffusion Pharmaceuticals GAAP EPS of -$2.22 | N/A | |
| 2022-04-18 14:12 EST | News | Diffusion Pharma crashes after announcing reverse stock split | N/A | |
| 2022-03-21 11:35 EST | News | Diffusion Pharmaceuticals GAAP EPS of -$0.25 | N/A | |
| 2021-11-22 22:37 EST | News | Dosing underway in Diffusion Pharma's Altitude trial | N/A | |
| 2021-11-11 04:34 EST | News | Diffusion Pharmaceuticals EPS misses by $0.08 | N/A | |
| 2021-08-30 10:40 EST | News | Diffusion Pharma gains 6% on FDA clearance of IND for TSC in lung disease | N/A | |
| 2021-08-11 19:18 EST | News | Diffusion Pharmaceuticals reports Q2 results | N/A | |
| 2021-08-11 19:17 EST | News | Diffusion provides COVID-19 study data timeline update, sees cash runway through 2023 | N/A | |
| 2021-07-21 03:58 EST | News | Diffusion Pharmaceuticals posts positive trend in oxygenation from TCOM trial | N/A | |
| 2021-03-25 12:19 EST | News | Diffusion Pharmaceuticals completes enrollment and dosing in Phase 1 TCOM study | N/A | |
| 2021-03-19 04:47 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-18 17:25 EST | News | Diffusion pharmaceuticals starts dosing in TCOM study | N/A | |
| 2021-03-18 12:30 EST | Earnings Estimate | An EPS average of -$0.20 is estimated for the 2022 year. | Sell | |
| 2021-03-17 21:31 EST | News | Diffusion Pharmaceuticals reports FY results | N/A | |
| 2021-03-14 13:15 EST | News | Diffusion Pharmaceutical (DFFN) Presents At HC Wainwright Global Life Sciences Conference | N/A | |
| 2021-02-17 19:46 EST | News | Diffusion Pharmaceuticals closes $30M bought deal offering | N/A | |
| 2021-02-17 02:13 EST | News | Diffusion Pharma completes early-stage study of TSC in COVID-19, shares up 18% | N/A | |
| 2021-02-12 17:15 EST | News | Diffusion Pharma plummets 18% on capital raise | N/A | |
| 2021-02-11 23:41 EST | News | Diffusion Pharmaceuticals stock slumps 11% as company raises $10M capital | N/A | |
| 2020-11-26 19:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-24 07:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 03:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 11:45 EST | Earnings Estimate | An EPS average of -$0.06 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-11-12 21:25 EST | News | Diffusion Pharmaceuticals EPS misses by $0.01 | N/A | |
| 2020-11-07 15:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 12:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-10 22:32 EST | News | Dosing is underway for Diffusion Pharma's lead asset in early-stage COVID-19 study | N/A | |
| 2020-09-09 17:26 EST | News | Diffusion Pharma names new CEO | N/A | |
| 2020-08-25 08:38 EST | Analyst Rating | The Analyst Target Price has decreased from $3.5 to $2.75. | Neutral | |
| 2020-08-14 08:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-10 10:35 EST | News | Diffusion Pharmaceuticals EPS misses by $0.04 | N/A | |
| 2020-08-09 00:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 00:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 20:02 EST | News | Diffusion Pharma changes design of early-stage study of TSC in COVID-19 | N/A | |
| 2020-07-23 16:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 08:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-08 08:12 EST | News | Diffusion Pharma files IND to launch COVID-19 program with trans sodium crocetinate | N/A | |
| 2020-07-08 08:11 EST | News | Diffusion Pharma to launch study of trans sodium crocetinate in COVID-19 | N/A | |
| 2020-07-01 08:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 12:40 EST | News | Diffusion Pharma to initiate early-stage TSC study in COVID-19 patients in Europe | N/A | |
| 2020-06-12 04:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-02 14:05 EST | News | Diffusion Pharmaceuticals regains Nasdaq compliance | N/A | |
| 2020-06-02 08:30 EST | Earnings Estimate | An EPS average of -$0.06 is estimated for the quarter ending on September 30, 2020. | Buy | |
| 2020-05-27 04:34 EST | Financials | Company financials have been released. | Neutral | |
About Diffusion Pharmaceuticals Inc (DFFN):
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.
General
- Name Diffusion Pharmaceuticals Inc
- Symbol DFFN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 10
- Last Split Factor1:15
- Last Split Date2018-12-14
- Fiscal Year EndDecember
- IPO Date2016-01-04
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.diffusionpharma.com
View More
Valuation
- Trailing PE 70
- Price/Book (Most Recent Quarter) 3.83
- Enterprise Value EBITDA 0.01
View More
Financials
- Most Recent Quarter 2020-09-30
- Current Year EPS Estimate -$0.19
- Next Year EPS Estimate -$0.20
- Next Quarter EPS Estimate -$0.05
- Return on Assets -39%
- Return on Equity -63%
- Earnings Per Share -$4.97
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 109.04 million
- EBITDA -11031373
- Analyst Target Price $2.75
- Book Value Per Share $0.39
View More
Share Statistics
- Shares Outstanding 101.9 million
- Shares Float 101.72 million
- % Held by Insiders 21%
- % Held by Institutions 10.71%
- Shares Short 1.82 million
- Shares Short Prior Month 517864
- Short Ratio 0.12
- Short % of Float 2%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 1.72
- 52 Week High $1.85
- 52 Week Low $0.28
- 50 Day Moving Average 1.17
- 200 Day Moving Average 0.93
View More
Dividends
- Dividend Date 2018-12-14
- ExDividend Date N/A
- Dividend Yield 0%
View More
Diffusion Pharmaceuticals Inc (DFFN) Dividend Calendar:
DFFN's last dividend payment was made to shareholders on December 14, 2018.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Diffusion Pharmaceuticals Inc (DFFN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | -$0.06 | -$0.05 | -20% |
| 2020-09-30 | 2020-11-12 | $N/A | -$0.07 | -$0.06 | -27.27% |
| 2020-06-30 | 2020-08-07 | $N/A | -$0.10 | -$0.06 | -81.82% |
| 2020-03-31 | 2020-05-11 | $N/A | -$0.07 | -$0.09 | 17.65% |
| 2019-12-31 | 2020-03-17 | $N/A | -$0.11 | -$0.13 | 15.38% |
| 2019-09-30 | 2019-11-08 | $N/A | -$0.60 | -$0.71 | 15.49% |
| 2019-06-30 | 2019-08-08 | $N/A | -$0.63 | -$0.90 | 30% |
| 2019-03-31 | 2019-05-09 | $N/A | -$0.81 | -$0.91 | 10.5% |
| 2018-12-31 | 2019-03-19 | $N/A | -$1.49 | -$0.90 | -65.56% |
| 2018-09-30 | 2018-11-13 | $N/A | -$1.95 | -$0.90 | -116.67% |
| 2018-06-30 | 2018-08-10 | $N/A | -$0.75 | -$0.90 | 16.67% |
| 2018-03-31 | 2018-05-10 | $N/A | -$4.05 | -$0.83 | -390.91% |
| 2017-12-31 | 2018-03-29 | $N/A | -$1.65 | -$0.60 | -175% |
| 2017-09-30 | 2017-11-13 | $N/A | $3.00 | -$6.45 | 146.51% |
| 2017-06-30 | 2017-08-14 | $N/A | $13.20 | -$5.55 | 337.84% |
| 2017-03-31 | 2017-05-15 | $N/A | -$41.70 | -$4.80 | -768.75% |
| 2016-12-31 | 2017-03-31 | $N/A | -$3.60 | -$5.10 | 29.41% |
| 2016-09-30 | 2016-11-14 | $N/A | -$7.95 | -$5.10 | -55.88% |
| 2016-06-30 | 2016-08-15 | $N/A | -$6.00 | -$4.50 | -33.33% |
| 2016-03-31 | 2016-05-16 | $N/A | -$9.34 | ||
| 2015-12-31 | 2016-03-25 | $N/A | -$25.50 | -$42.00 | 39.29% |
| 2015-09-30 | 2015-11-12 | $N/A | -$106.56 | ||
| 2015-06-30 | 2015-08-12 | $N/A | -$2.10 | -$1.80 | -16.67% |
| 2015-03-31 | 2015-04-03 | $N/A | -$1.90 | -$1.70 | -11.76% |
| 2014-12-31 | 2015-02-25 | $N/A | -$40.84 | ||
| 2014-09-30 | 2014-11-12 | $N/A | -$27.71 | ||
| 2014-06-30 | 2014-08-14 | $N/A | -$51.93 | ||
| 2014-03-31 | 2014-03-31 | $N/A | -$34.89 | ||
| 2013-12-31 | 2013-12-31 | -$20.89 | |||
| 2013-09-30 | 2013-09-30 | $N/A | -$55.21 | ||
| 2013-06-30 | 2013-06-30 | $N/A | $120.54 | ||
| 2013-03-31 | 2013-03-31 | -$437.13 | |||
| 2012-12-31 | 2012-12-31 | $331.84 | |||
| 2012-09-30 | 2012-09-30 | $N/A | -$579.01 | ||
| 2012-06-30 | 2012-06-30 | -$574.00 | |||
| 2012-03-31 | 2012-03-31 | -$421.74 | |||
| 2011-12-31 | 2011-12-31 | -$1,512.45 | |||
| 2011-09-30 | 2011-09-30 | $N/A | -$838.80 | ||
| 2011-03-31 | 2011-03-31 | -$400.41 | |||
| 2010-12-31 | 2010-12-31 | -$190.12 | |||
| 2010-09-30 | 2010-09-30 | -$439.68 | |||
| 2009-12-31 | 2009-12-31 | -$447.76 | |||
| 2009-09-30 | 2009-09-30 | -$155.32 | |||
| 2009-06-30 | 2009-06-30 | -$163.82 | |||
| 2009-03-31 | 2009-03-31 | -$107.00 | |||
| 2008-12-31 | 2008-12-31 | -$435.24 | |||
| 2008-09-30 | 2008-09-30 | -$73.19 | |||
| 2008-06-30 | 2008-06-30 | -$78.04 | |||
| 2008-03-31 | 2008-03-31 | $19.69 | |||
| 2007-09-30 | 2007-09-30 | -$1,614.35 | |||
| 2007-06-30 | 2007-06-30 | -$5,411.62 | |||
| 2007-03-31 | 2007-03-31 | -$665.03 | |||
| 2000-09-30 | 2000-09-30 | -$1,000,000.00 | |||
| 2000-06-30 | 2000-06-30 | -$741,485.61 | |||
| 2000-03-31 | 2000-03-31 | -$513,519.81 | |||
| 1999-03-31 | 1999-03-31 | -$58,286.94 | |||
| 1998-12-31 | 1998-12-31 | -$89,542.36 | |||
| 1998-09-30 | 1998-09-30 | $75,258.19 |
Diffusion Pharmaceuticals Inc (DFFN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | 1.53 million | 1.66 million |
| Income Before Tax | N/A | N/A | N/A | -2.92 million | -2.93 million |
| Selling General Administrative | N/A | N/A | N/A | 1.39 million | 1.27 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | N/A | N/A | N/A | -2.93 million | -2.96 million |
| Operating Income | N/A | N/A | N/A | -2.96 million | -2.96 million |
| Income Tax Expense | N/A | -805676 | -507325 | N/A | 818101 |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 25706 |
| Net Income From Continuing Operations | N/A | N/A | N/A | -2.56 million | -3.75 million |
| Net Income Applicable to Common Shares | -4.06 million | -4.44 million | -5.08 million | N/A | -3.75 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | 1.05 million | 606900 | N/A | 264202 | 255146 |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | 155193 | 10.48 million | -80206 |
| Change to Operating Activities | 380334 | -258528 | N/A | 74522 | 458642 |
| Change in Cash | N/A | N/A | -3.35 million | 8.04 million | -2.23 million |
| Total Cash from Operating Activities | -3.51 million | -3.14 million | -3.5 million | -2.44 million | -2.15 million |
| Depreciation | N/A | N/A | 27020 | 27075 | 18178 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | -148900 | -595196 | N/A | N/A | -80206 |
| Change to Net Income | -526203 | -393881 | N/A | 948258 | -80639 |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | 3.16 million | 3.98 million |
| Total Stockholder Equity | N/A | N/A | N/A | 17.9 million | 20.13 million |
| Other Current Liabilities | N/A | N/A | N/A | 22205 | N/A |
| Total Assets | N/A | N/A | N/A | 21.06 million | 24.11 million |
| Common Stock | 64016 | 64016 | 63999 | N/A | 33481 |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -105.91 million | -101.85 million | -97.41 million | -94.28 million | -91.72 million |
| Other Liabilities | 443893 | 443893 | 1.25 million | N/A | 2.12 million |
| Other Assets | 15771 | 252057 | 252149 | N/A | 322301 |
| Cash | N/A | N/A | N/A | 10.83 million | 14.18 million |
| Total Current Liabilities | 2.44 million | 2.69 million | N/A | 1.29 million | 1.72 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 298360 | 348801 | 393204 | N/A | 499409 |
| Total Current Assets | 18.78 million | 22.68 million | N/A | 11.72 million | 14.65 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 16.18 million | 20.09 million | 24.24 million | N/A | 11.5 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 545844 | 1.41 million | N/A | 655298 | 1.25 million |
Diffusion Pharmaceuticals Inc (DFFN) Chart:
Diffusion Pharmaceuticals Inc (DFFN) News:
Below you will find a list of latest news for Diffusion Pharmaceuticals Inc (DFFN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Diffusion Pharmaceuticals Inc (DFFN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest DFFN Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 5:46 PM EST | 100 | $7.52 |
| Jun 13, 2022 5:46 PM EST | 100 | $7.54 |
| Jun 13, 2022 6:51 PM EST | 100 | $7.53 |
| Jun 13, 2022 7:44 PM EST | 2 | $7.4 |
| Jun 13, 2022 7:59 PM EST | 100 | $7.72 |
Diffusion Pharmaceuticals Inc (DFFN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920013423/0001437749-20-013423-index.htm |
| 2018-02-12 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1053691/000000000018004839/0000000000-18-004839-index.htm |
| 2019-05-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1053691/000000000019008805/0000000000-19-008805-index.htm |
| 2019-09-16 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1053691/000000000019013592/0000000000-19-013592-index.htm |
| 2019-10-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1053691/000000000019014765/0000000000-19-014765-index.htm |
| 2019-12-23 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1053691/000000000019016775/0000000000-19-016775-index.htm |
| 2020-06-02 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1053691/000000000020004919/0000000000-20-004919-index.htm |
| 2020-09-29 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1053691/000000000020009153/0000000000-20-009153-index.htm |
| 2019-06-03 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1053691/000091957419003945/0000919574-19-003945-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1053691/000091957420001439/0000919574-20-001439-index.htm |
| 2018-01-29 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1053691/000119312518023271/0001193125-18-023271-index.htm |
| 2019-06-03 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1053691/000119312519163505/0001193125-19-163505-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1053691/000119312520038074/0001193125-20-038074-index.htm |
| 2019-11-25 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1053691/000121390019024508/0001213900-19-024508-index.htm |
| 2019-12-20 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1053691/000121390019026687/0001213900-19-026687-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000258/0001437749-18-000258-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000259/0001437749-18-000259-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000260/0001437749-18-000260-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000261/0001437749-18-000261-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000263/0001437749-18-000263-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000264/0001437749-18-000264-index.htm |
| 2018-01-16 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000686/0001437749-18-000686-index.htm |
| 2018-01-16 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000700/0001437749-18-000700-index.htm |
| 2018-01-17 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000721/0001437749-18-000721-index.htm |
| 2018-01-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000800/0001437749-18-000800-index.htm |
| 2018-01-19 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000841/0001437749-18-000841-index.htm |
| 2018-01-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918000941/0001437749-18-000941-index.htm |
| 2018-02-06 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774918001767/0001437749-18-001767-index.htm |
| 2018-02-12 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774918002214/0001437749-18-002214-index.htm |
| 2018-02-14 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774918002562/0001437749-18-002562-index.htm |
| 2018-03-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918003914/0001437749-18-003914-index.htm |
| 2018-03-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918004965/0001437749-18-004965-index.htm |
| 2018-04-02 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1053691/000143774918006050/0001437749-18-006050-index.htm |
| 2018-04-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918006155/0001437749-18-006155-index.htm |
| 2018-04-20 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1053691/000143774918007347/0001437749-18-007347-index.htm |
| 2018-04-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1053691/000143774918008132/0001437749-18-008132-index.htm |
| 2018-04-30 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1053691/000143774918008133/0001437749-18-008133-index.htm |
| 2018-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774918009433/0001437749-18-009433-index.htm |
| 2018-05-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918009449/0001437749-18-009449-index.htm |
| 2018-06-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918011908/0001437749-18-011908-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774918012012/0001437749-18-012012-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774918012013/0001437749-18-012013-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774918012014/0001437749-18-012014-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774918012015/0001437749-18-012015-index.htm |
| 2018-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774918015223/0001437749-18-015223-index.htm |
| 2018-08-10 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1053691/000143774918015228/0001437749-18-015228-index.htm |
| 2018-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918015601/0001437749-18-015601-index.htm |
| 2018-08-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918016475/0001437749-18-016475-index.htm |
| 2018-09-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918017551/0001437749-18-017551-index.htm |
| 2018-10-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774918017902/0001437749-18-017902-index.htm |
| 2018-11-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774918020566/0001437749-18-020566-index.htm |
| 2018-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918020812/0001437749-18-020812-index.htm |
| 2018-12-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774918021995/0001437749-18-021995-index.htm |
| 2019-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774919000343/0001437749-19-000343-index.htm |
| 2019-01-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919001064/0001437749-19-001064-index.htm |
| 2019-01-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774919001522/0001437749-19-001522-index.htm |
| 2019-03-19 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1053691/000143774919005256/0001437749-19-005256-index.htm |
| 2019-04-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1053691/000143774919008328/0001437749-19-008328-index.htm |
| 2019-04-30 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1053691/000143774919008329/0001437749-19-008329-index.htm |
| 2019-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774919009285/0001437749-19-009285-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919009288/0001437749-19-009288-index.htm |
| 2019-05-16 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774919010251/0001437749-19-010251-index.htm |
| 2019-05-22 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774919010685/0001437749-19-010685-index.htm |
| 2019-05-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774919010847/0001437749-19-010847-index.htm |
| 2019-05-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919010905/0001437749-19-010905-index.htm |
| 2019-06-03 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774919011280/0001437749-19-011280-index.htm |
| 2019-06-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919011940/0001437749-19-011940-index.htm |
| 2019-07-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774919014277/0001437749-19-014277-index.htm |
| 2019-07-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774919014278/0001437749-19-014278-index.htm |
| 2019-07-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774919014279/0001437749-19-014279-index.htm |
| 2019-08-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774919015539/0001437749-19-015539-index.htm |
| 2019-08-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774919015540/0001437749-19-015540-index.htm |
| 2019-08-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774919015541/0001437749-19-015541-index.htm |
| 2019-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774919016051/0001437749-19-016051-index.htm |
| 2019-08-20 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1053691/000143774919017198/0001437749-19-017198-index.htm |
| 2019-09-09 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774919018077/0001437749-19-018077-index.htm |
| 2019-09-26 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774919019093/0001437749-19-019093-index.htm |
| 2019-09-27 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774919019129/0001437749-19-019129-index.htm |
| 2019-10-04 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774919019717/0001437749-19-019717-index.htm |
| 2019-10-10 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774919019919/0001437749-19-019919-index.htm |
| 2019-10-16 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774919020133/0001437749-19-020133-index.htm |
| 2019-10-28 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774919020753/0001437749-19-020753-index.htm |
| 2019-10-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774919020757/0001437749-19-020757-index.htm |
| 2019-10-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774919020758/0001437749-19-020758-index.htm |
| 2019-10-30 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774919020944/0001437749-19-020944-index.htm |
| 2019-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774919022149/0001437749-19-022149-index.htm |
| 2019-11-08 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774919022192/0001437749-19-022192-index.htm |
| 2019-11-08 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774919022194/0001437749-19-022194-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919022309/0001437749-19-022309-index.htm |
| 2019-11-13 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774919022543/0001437749-19-022543-index.htm |
| 2019-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919022699/0001437749-19-022699-index.htm |
| 2019-11-15 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774919022972/0001437749-19-022972-index.htm |
| 2019-11-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919023055/0001437749-19-023055-index.htm |
| 2019-11-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919023215/0001437749-19-023215-index.htm |
| 2019-12-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919024112/0001437749-19-024112-index.htm |
| 2019-12-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919024137/0001437749-19-024137-index.htm |
| 2019-12-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919024211/0001437749-19-024211-index.htm |
| 2019-12-13 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774919024368/0001437749-19-024368-index.htm |
| 2019-12-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919024424/0001437749-19-024424-index.htm |
| 2019-12-17 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774919024544/0001437749-19-024544-index.htm |
| 2019-12-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774919024718/0001437749-19-024718-index.htm |
| 2019-12-20 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774919024737/0001437749-19-024737-index.htm |
| 2019-12-23 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774919024829/0001437749-19-024829-index.htm |
| 2019-12-30 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774919024983/0001437749-19-024983-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920000403/0001437749-20-000403-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920000523/0001437749-20-000523-index.htm |
| 2020-01-13 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920000548/0001437749-20-000548-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920000552/0001437749-20-000552-index.htm |
| 2020-01-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920001420/0001437749-20-001420-index.htm |
| 2020-01-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920001421/0001437749-20-001421-index.htm |
| 2020-01-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920001423/0001437749-20-001423-index.htm |
| 2020-02-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920001905/0001437749-20-001905-index.htm |
| 2020-03-17 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1053691/000143774920005469/0001437749-20-005469-index.htm |
| 2020-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920005589/0001437749-20-005589-index.htm |
| 2020-03-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920006025/0001437749-20-006025-index.htm |
| 2020-04-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920006773/0001437749-20-006773-index.htm |
| 2020-04-17 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1053691/000143774920007972/0001437749-20-007972-index.htm |
| 2020-04-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920008768/0001437749-20-008768-index.htm |
| 2020-04-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1053691/000143774920008837/0001437749-20-008837-index.htm |
| 2020-04-29 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1053691/000143774920008838/0001437749-20-008838-index.htm |
| 2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920009524/0001437749-20-009524-index.htm |
| 2020-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920010091/0001437749-20-010091-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774920010278/0001437749-20-010278-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920010323/0001437749-20-010323-index.htm |
| 2020-05-13 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1053691/000143774920010606/0001437749-20-010606-index.htm |
| 2020-05-15 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920011014/0001437749-20-011014-index.htm |
| 2020-05-19 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774920011311/0001437749-20-011311-index.htm |
| 2020-05-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920011442/0001437749-20-011442-index.htm |
| 2020-05-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920011445/0001437749-20-011445-index.htm |
| 2020-05-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920011747/0001437749-20-011747-index.htm |
| 2020-05-27 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920011845/0001437749-20-011845-index.htm |
| 2020-05-29 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774920012079/0001437749-20-012079-index.htm |
| 2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920012220/0001437749-20-012220-index.htm |
| 2020-06-03 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774920012354/0001437749-20-012354-index.htm |
| 2020-06-03 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774920012357/0001437749-20-012357-index.htm |
| 2020-06-08 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774920012632/0001437749-20-012632-index.htm |
| 2020-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920013000/0001437749-20-013000-index.htm |
| 2020-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920013327/0001437749-20-013327-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920013420/0001437749-20-013420-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920013421/0001437749-20-013421-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920013422/0001437749-20-013422-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920013423/0001437749-20-013423-index.htm |
| 2020-07-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920014790/0001437749-20-014790-index.htm |
| 2020-07-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920015912/0001437749-20-015912-index.htm |
| 2020-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774920017080/0001437749-20-017080-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920017366/0001437749-20-017366-index.htm |
| 2020-09-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920019346/0001437749-20-019346-index.htm |
| 2020-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920019460/0001437749-20-019460-index.htm |
| 2020-09-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920019576/0001437749-20-019576-index.htm |
| 2020-09-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920019648/0001437749-20-019648-index.htm |
| 2020-09-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920019730/0001437749-20-019730-index.htm |
| 2020-09-25 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1053691/000143774920020243/0001437749-20-020243-index.htm |
| 2020-09-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920020264/0001437749-20-020264-index.htm |
| 2020-09-30 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1053691/000143774920020475/0001437749-20-020475-index.htm |
| 2020-10-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920020634/0001437749-20-020634-index.htm |
| 2020-10-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920020635/0001437749-20-020635-index.htm |
| 2020-10-02 | 424B2 | Prospectus [Rule 424(b)(2)] | https://www.sec.gov/Archives/edgar/data/1053691/000143774920020672/0001437749-20-020672-index.htm |
| 2020-10-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920020986/0001437749-20-020986-index.htm |
| 2020-10-14 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920021142/0001437749-20-021142-index.htm |
| 2020-10-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920021143/0001437749-20-021143-index.htm |
| 2020-10-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1053691/000143774920021340/0001437749-20-021340-index.htm |
| 2020-10-21 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920021434/0001437749-20-021434-index.htm |
| 2020-10-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1053691/000143774920021435/0001437749-20-021435-index.htm |
| 2019-05-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1053691/000153561019000088/0001535610-19-000088-index.htm |
| 2020-01-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1053691/000153561020000025/0001535610-20-000025-index.htm |
| 2018-01-17 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1053691/999999999518000143/9999999995-18-000143-index.htm |
| 2018-02-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1053691/999999999518000437/9999999995-18-000437-index.htm |
| 2019-05-22 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1053691/999999999519001185/9999999995-19-001185-index.htm |
| 2019-10-08 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1053691/999999999519002273/9999999995-19-002273-index.htm |
| 2019-11-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1053691/999999999519002563/9999999995-19-002563-index.htm |
| 2019-12-27 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1053691/999999999519002944/9999999995-19-002944-index.htm |
| 2020-06-05 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1053691/999999999520001389/9999999995-20-001389-index.htm |
| 2020-10-02 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1053691/999999999520002734/9999999995-20-002734-index.htm |